Biophan Technologies, Inc. Company Overview and Update

1. Biophan Technologies, Inc.Company Overview and Update Michael Weiner, CEO Stephens 2005 Nanotechnology Investors Conference April 6, 2005

2. Cautionary Statement Certain statements included in this presentation may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this presentation should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference.  The forward-looking statements contained herein are made only as of the date of this presentation, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

3. Biophan’s Mission • Enable over $12 billion worth of medical devices shipping annually safe for use with MRI, and imageable. Many are not: • Guidewires, catheters, endoscopes, biopsy needles • Pacemakers, defibrillators, neurostimulators, drug pumps (safety issues, also imaging issues), pain control devices • Stents, embolism clips, aneurysm clips, artificial hips, knees, most other orthopedics • Bring other innovations for competitive advantage to biomedical device and pharmaceutical companies.

4. Biophan’s Solutions • MRI Safety: (many products contraindicated) • RF filter from Johns Hopkins (heating) • “Anti-Antenna” lead design (heating & induced voltages) • MRI Safe non-magnetic motor • Nanomagnetic particle technologies • Minimize image artifacts • Makes catheters, guidewires, stents, etc. visible under MRI • Contrast agents • Drug Delivery

5. PROTECTED, PROTECTED! • Technologies covered by • 114 U.S. Patents • 36 ISSUED • 72 pending or allowed • Owned by Biophan or licensed exclusively to Biophan for the medical market • Plus many International patents

6. MRI Device Imaging Biophan’s thin-film nanomagnetic particle coating technology provides a controllable, “magnetic” signal capable of creating an image of the coated device. #3 is uncoated. 1 2 3 SE coronal image of 3 aluminum wires (1/32”). Wire (3) is uncoated.

7. Making Stents Imageable • Seeing blockage of stents has required an invasive procedure • Stents imageable under MRI would be competitively advantaged • Nanoset has a nanomagnetic particle, thin film coating • AMRIS, now Biophan-Europe, has a “retrofit” solution • Both solutions are PATENTED!

8. Implications • Impact the $5+ billion stent market • Help manufacturers make pacemakers, defibrillators, neurostimulators safe, and imageable – competitive advantage to our licensees • Make guidewires, catheters, endoscopes, biopsy needles safe and image compatible • Opens the field of interventional medicine under MRI (currently only X-Ray/Fluoroscopy)

9. Biothermal Battery • Goal: To provide a long-lived electrical power system for implanted medical devices • Powered by body heat differential. • Batteries are a $500 million market, sell for $100 to $225 each in the pacemaker, defibrillator and drug pump markets • Sold to same customers who need MRI safety • Nanomaterials brings this capability within striking distance. We hold issues and pending patents

10. Agreement with NASA • Announced on August 17th a deal with NASA Ames Research Center for Nanotechnology to jointly develop the biothermal battery • NASA wants technology for their long duration manned MARS mission for biosensing and miniature therapeutic devices • Biophan gets commercial rights to jointly developed and NASA developed technology • Nanotechnology and materials science advances makes the biothermal battery possible

11. Non-Magnetic MRI-Safe and Imageable Greater efficiency Enables precision 20 nm movements Ideal for drug pumps, cryogenic applications, implantables Biophan holds worldwide medical distribution rights, + equity

12. Particle type A Drug A Drug bound to NMP carrier Particle type B Drug B Surface Elution on Demand Controlled Magnetic Field A Controlled Magnetic Field Controlled Magnetic Field B Polymer Coating Nanomagnetic layer Substrate

13. Drug bound to NMP carrier Reloading Drug Eluting Coatings Concentration Gradient Drug Molecules Controlled Magnetic Field Polymer Coating Nanomagnetic layer Substrate

14. Apply magnetic field to concentrate particles Inject NMPs IV, NMP will circulate through the blood stream Modulate field to release drug from particles Guided Drug Delivery Other options for targeting: 1 - Direct injection into tumor site 2 - Coating NMP with antibodies to target tumor Solid tumor

15. Markets • Medical devices (safe and/or image): $12 billion • Battery: $500 million • Contrast Agents: $800 million • Drug Pumps: $1 billion • Drug Delivery: $40 billion • Once deal is underway, patents and annuity streams can last a long time; • We anticipate money on signing, in development; plus milestones, royalties, high margin components

16. Business Model • Offering our customers competitive advantage • Through proprietary solutions that can gain marketshare for them • FDA approval is pursued by the customer • Marketing and distribution of the final device is their responsibility • We sell high margin components and develop annuities for our shareholders

17. Relationship With Boston Scientific • Joint development agreement, originally entered into November, 2003 • Recently moved to second and third phase, and has expanded to multiple products • Reached agreement on term sheet, working on final contract phase

18. Summary Financial Information • Share Price (04.6.05): $3.00 • 52-Week High: $3.50 • 52 Week Low: $0.46 • Shares Outstanding: 74 million • Float: 58 million • Market Cap: $222 million • Average Daily Volume: 1,023,272

19. BIOPHAN (OTCBB: BIPH)

20. Management • Stu MacDonald, VP R&D – formerly VP R&D at J&J division, with a 400 person organization • Jeff Helfer, VP Engineering – formerly Dir. Of Engineering at the same J&J division • John Lanzafame, President, Nanolution Division – former President STS Biopolymers, acquired by Angiotech (ANPI) • Robert Wood, VP Finance, Treasurer, Secretary, and CFO – CPA in public and private firms • Michael Friebe, Ph.D. • Andreas Melzer, MD

21. Biophan (OTC: BIPH) We don’t make medical devices; We make them safe, and imageable, for MRI And other competitive advantages for our customers Four of our six technologies are based on nanotechnology WWW.BIOPHAN.COM